Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas (352 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 1998 Jan; 83(1): 248-252.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 5.641, 5-year impact factor: 6.004
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-0031594761&partnerID=40&md5=863ea101e51a0b8650d90d164177ea78
Keywords: 3 Iodo 6 Methoxybenzamide I 123, Bromocriptine, Growth Hormone, Octreotide, Quinagolide, Radiopharmaceutical Agent, Somatomedin C, Unclassified Drug, 3 Iodo 2 Hydroxy 6 Methoxy N ((1 Ethyl 2 Pyrrolidinyl)methyl)benzamide, 3-Iodo-2-Hydroxy-6-Methoxy-N-((1-Ethyl-2-Pyrrolidinyl)methyl)benzamide, Aminoquinoline Derivative, Benzamide Derivative, Biological Marker, Diagnostic Agent, Dopamine Receptor Stimulating Agent, Human Growth Hormone, Prolactin, Pyrrolidine Derivative, Radioactive Iodine, Adult, Article, Brain Scintiscanning, Clinical Article, Controlled Study, Female, Growth Hormone Blood Level, Hypophysis Adenoma, Patient Monitoring, Prediction, Priority Journal, Single Photon Emission Computer Tomography, Treatment Outcome, Alpha Chain, Clinical Trial, Hypophysis Tumor, Nuclear Magnetic Resonance Imaging, Pathology, Secretion, Dopamine Agonists, Glycoprotein Hormones, Alpha Subunit, Insulin-Like Growth Factor I, Iodine Radioisotopes, Pituitary Neoplasms, Emission-Computed, Single-Photon, 3 Iodo 2 Hydroxy 6 Methoxy N ((1 Ethyl 2 Pyrrolidinyl) Methyl) Benzamide, 3-Iodo-2-Hydroxy-6-Methoxy-N-((1-Ethyl-2-Pyrrolidinyl) Methyl) Benzamide,
Affiliations:
Dept. Molec. Clin. Endocrinol. O., Federico II University, 080131 Naples, Italy
Department of Nuclear Medicine, National Cancer Institute, Fondazione G. Pascale, 080131 Naples, Italy
CNR, 080131 Naples, Italy
References:
Bevan, J.S., Webster, J., Burke, C.W., Scanlon, M.F., Dopamine agonists and pituitary tumor shrinkage (1992) Endocr Rev., 13, pp. 220-24
Melmed, S., Ho, K., Klibanski, A., Reichlin, S., Thorner, M., Recent advances in pathology, diagnosis and management of acromegaly (1995) J Clin Endocrinol Metab., 80, pp. 3395-3402
Colao, A., Ferone, D., Marzullo, P., Effect of different dopaminergic agents in the treatment of acromegaly (1997) J Clin Endocrinol Metab., 82, pp. 518-523
Yamada, S., Asa, S.L., Kovaks, K., Muller, P., Smyth, H.S., Analysis of hormone secretion by clinically nonfunctioning human pituitary adenomas using the reverse hemolytic plaque assay (1989) J Clin Endocrinol Metab., 68, pp. 73-80
Saccomanno, K., Gil-del-Alamo, P., Bassetti, M., Reza-Elahi, F., Spada, A., In vitro detection of glycoprotein production and secretion by human nonfunctioning pituitary adenomas (1993) J Endocrinol Invest., 16, pp. 109-115
Closse, A., Cramps, M., Wanner, A., Palacios, J.M., In vivo labelling of brain dopamine D2 receptors using the high-affinity specific D2 agonist (3H)CV 205-502 (1988) Brain Res., 440, pp. 123-128
Brue, T., Pellegrini, I., Gunz, G., Effects of dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine (1992) J Clin Endocrinol Metab., 74, pp. 577-584
Colao, A., Merola, B., Sarnacchiaro, F., Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas (1995) Horm Res., 44, pp. 222-228
Chiodini, P.G., Attanasio, R., Cozzi, R., CV 205-502 in acromegaly (1993) Acta Endocrinol, 128, pp. 389-393. , Copenh
Lombardi, G., Colao, A., Ferone, D., CV 205-502 treatment in therapy-resistant acromegalic patients (1995) Eur J Endocrinol., 132, pp. 559-564
Kwekkeboom, D.J., Lamberts, S.W.J., Long-term treatment with dopamine agonist CV 205-502 of patients with clinically non-functioning, gonadotroph, or α-subunit secreting pituitary adenoma (1992) Clin Endocrinol, 36, pp. 171-176. , Oxf
Brücke, T., Wenger, S., Asenbaum, S., Dopamine D2 receptor imaging and measurements with SPECT (1993) Adv Neurol., 60, pp. 494-500
De Herder, W.W., Reijs, A.E.M., Kwekkeboom, D.J., In vivo imaging of pituitary tumors using a radiolabeled dopamine D2 receptor radioligand (1996) Clin Endocrinol, 45, pp. 755-767. , Oxf
Scillitani, A., Dicembrino, F., Di Fazio, P., In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxybenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas (1995) J Clin Endocrinol Metab., 80, pp. 2523-2525
Verhoeff, N.P., Bemelman, F.J., Wiersinga, W.M., Van Royen, E.A., Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with TSH/PRL-producing pituitary macroadenoma (1993) Eur J Nucl Med., 20, pp. 555-561
Verhoeff, N.P., Van Royen, E.A., Van Royen, N., Dopamine D2-receptor imaging with dynamic I-123 iodo benzamide SPECT in healthy human volunteers (1991) J Nucl Med., 32, pp. 1076-1079
Ebersold, M.J., Quast, L.M., Laws, E.R., Long-term results in transsphenoidal removal of nonfunctioning pituitary adenomas (1986) J Neurosurg., 334, pp. 246-254
Harris, P.E., Afshar, F., Coates, P., The effects of transsphenoidal surgery on endocrine function and visual fields in patients with functionless pituitary adenomas (1989) Q J Med New Series, 71, p. 417
Littley, M.D., Shalet, S.M., Beardwell, C.G., Ahmed, S.R., Applegate, G., Sutton, M.I., Hypopituitarism following external radiotherapy for pituitary tumors in adults (1989) Q J Med New Series, 70, p. 145
Warnet, A., Timsit, J., Chanson, P., The effect of somatostatin analogue on chiasmal dysfunction from pituitary macroadenomas (1989) J Neurosurg., 71, pp. 687-690
De Bruin, T.W.A., Kwekkeboom, D.J., Van't Verlaat, J.W., Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro (1992) J Clin Endocrinol Metab., 75, pp. 1310-1317
Merola, B., Colao, A., Ferone, D., Effects of chronic treatment with octreotide in patients with functionless pituitary adenomas (1993) Horm Res., 40, pp. 149-155
Plöckinger, U., Reichel, M., Fett, U., Saeger, W., Quabbe, H.J., Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: Effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy (1994) J Clin Endocrinol Metab., 79, pp. 1416-1423
Bevan, J.S., Burke, C.W., Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine (1986) Clin Endocrinol, 25, pp. 561-572. , Oxf
Koga, M., Nakao, H., Arao, M., Demonstration of specific dopamine receptors on human pituitary adenomas (1987) Acta Endocrinol, 114, pp. 595-602. , Copenh
De Herder, W.W., Lamberts, S.W.J., Imaging of pituitary tumours (1995) Baillieres Clin Endocrinol Metab., 9, pp. 367-389
Leslie, W.D., Abrams, D.N., Greenberg, C.R., Hobson, D., Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging (1996) J Nucl Med., 37, pp. 1589-1591
Pirker, W., Riedl, M., Luger, A., Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT (1996) J Nucl Med., 37, pp. 1931-1937
Pirker, W., Brücke, T., Riedl, M., Iodine-123-IBZM-SPECT: Studies in 15 patients with pituitary tumors (1994) J Neural Transm., 97, pp. 235-244
Bevan, J. S., Webster, J., Burke, C. W., Scanlon, M. F., Dopamine agonists and pituitary tumor shrinkage (1992) Endocr Rev., 13, pp. 220-24
Chiodini, P. G., Attanasio, R., Cozzi, R., CV 205-502 in acromegaly (1993) Acta Endocrinol, 128, pp. 389-393. , Copenh
Kwekkeboom, D. J., Lamberts, S. W. J., Long-term treatment with dopamine agonist CV 205-502 of patients with clinically non-functioning, gonadotroph, or -subunit secreting pituitary adenoma (1992) Clin Endocrinol, 36, pp. 171-176. , Oxf
Br cke, T., Wenger, S., Asenbaum, S., Dopamine D2 receptor imaging and measurements with SPECT (1993) Adv Neurol., 60, pp. 494-500
De Herder, W. W., Reijs, A. E. M., Kwekkeboom, D. J., In vivo imaging of pituitary tumors using a radiolabeled dopamine D2 receptor radioligand (1996) Clin Endocrinol, 45, pp. 755-767. , Oxf
Verhoeff, N. P., Bemelman, F. J., Wiersinga, W. M., Van Royen, E. A., Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with TSH/PRL-producing pituitary macroadenoma (1993) Eur J Nucl Med., 20, pp. 555-561
Verhoeff, N. P., Van Royen, E. A., Van Royen, N., Dopamine D2-receptor imaging with dynamic I-123 iodo benzamide SPECT in healthy human volunteers (1991) J Nucl Med., 32, pp. 1076-1079
Ebersold, M. J., Quast, L. M., Laws, E. R., Long-term results in transsphenoidal removal of nonfunctioning pituitary adenomas (1986) J Neurosurg., 334, pp. 246-254
Harris, P. E., Afshar, F., Coates, P., The effects of transsphenoidal surgery on endocrine function and visual fields in patients with functionless pituitary adenomas (1989) Q J Med New Series, 71, p. 417
Littley, M. D., Shalet, S. M., Beardwell, C. G., Ahmed, S. R., Applegate, G., Sutton, M. I., Hypopituitarism following external radiotherapy for pituitary tumors in adults (1989) Q J Med New Series, 70, p. 145
De Bruin, T. W. A., Kwekkeboom, D. J., Van't Verlaat, J. W., Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro (1992) J Clin Endocrinol Metab., 75, pp. 1310-1317
Pl ckinger, U., Reichel, M., Fett, U., Saeger, W., Quabbe, H. J., Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: Effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy (1994) J Clin Endocrinol Metab., 79, pp. 1416-1423
Bevan, J. S., Burke, C. W., Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine (1986) Clin Endocrinol, 25, pp. 561-572. , Oxf
De Herder, W. W., Lamberts, S. W. J., Imaging of pituitary tumours (1995) Baillieres Clin Endocrinol Metab., 9, pp. 367-389
Leslie, W. D., Abrams, D. N., Greenberg, C. R., Hobson, D., Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging (1996) J Nucl Med., 37, pp. 1589-1591
Pirker, W., Br cke, T., Riedl, M., Iodine-123-IBZM-SPECT: Studies in 15 patients with pituitary tumors (1994) J Neural Transm., 97, pp. 235-244
J Clin Endocrinol Metab (ISSN: 0021-972x), 1998 Jan; 83(1): 248-252.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 5.641, 5-year impact factor: 6.004
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-0031594761&partnerID=40&md5=863ea101e51a0b8650d90d164177ea78
Keywords: 3 Iodo 6 Methoxybenzamide I 123, Bromocriptine, Growth Hormone, Octreotide, Quinagolide, Radiopharmaceutical Agent, Somatomedin C, Unclassified Drug, 3 Iodo 2 Hydroxy 6 Methoxy N ((1 Ethyl 2 Pyrrolidinyl)methyl)benzamide, 3-Iodo-2-Hydroxy-6-Methoxy-N-((1-Ethyl-2-Pyrrolidinyl)methyl)benzamide, Aminoquinoline Derivative, Benzamide Derivative, Biological Marker, Diagnostic Agent, Dopamine Receptor Stimulating Agent, Human Growth Hormone, Prolactin, Pyrrolidine Derivative, Radioactive Iodine, Adult, Article, Brain Scintiscanning, Clinical Article, Controlled Study, Female, Growth Hormone Blood Level, Hypophysis Adenoma, Patient Monitoring, Prediction, Priority Journal, Single Photon Emission Computer Tomography, Treatment Outcome, Alpha Chain, Clinical Trial, Hypophysis Tumor, Nuclear Magnetic Resonance Imaging, Pathology, Secretion, Dopamine Agonists, Glycoprotein Hormones, Alpha Subunit, Insulin-Like Growth Factor I, Iodine Radioisotopes, Pituitary Neoplasms, Emission-Computed, Single-Photon, 3 Iodo 2 Hydroxy 6 Methoxy N ((1 Ethyl 2 Pyrrolidinyl) Methyl) Benzamide, 3-Iodo-2-Hydroxy-6-Methoxy-N-((1-Ethyl-2-Pyrrolidinyl) Methyl) Benzamide,
Affiliations:
Dept. Molec. Clin. Endocrinol. O., Federico II University, 080131 Naples, Italy
Department of Nuclear Medicine, National Cancer Institute, Fondazione G. Pascale, 080131 Naples, Italy
CNR, 080131 Naples, Italy
References:
Bevan, J.S., Webster, J., Burke, C.W., Scanlon, M.F., Dopamine agonists and pituitary tumor shrinkage (1992) Endocr Rev., 13, pp. 220-24
Melmed, S., Ho, K., Klibanski, A., Reichlin, S., Thorner, M., Recent advances in pathology, diagnosis and management of acromegaly (1995) J Clin Endocrinol Metab., 80, pp. 3395-3402
Colao, A., Ferone, D., Marzullo, P., Effect of different dopaminergic agents in the treatment of acromegaly (1997) J Clin Endocrinol Metab., 82, pp. 518-523
Yamada, S., Asa, S.L., Kovaks, K., Muller, P., Smyth, H.S., Analysis of hormone secretion by clinically nonfunctioning human pituitary adenomas using the reverse hemolytic plaque assay (1989) J Clin Endocrinol Metab., 68, pp. 73-80
Saccomanno, K., Gil-del-Alamo, P., Bassetti, M., Reza-Elahi, F., Spada, A., In vitro detection of glycoprotein production and secretion by human nonfunctioning pituitary adenomas (1993) J Endocrinol Invest., 16, pp. 109-115
Closse, A., Cramps, M., Wanner, A., Palacios, J.M., In vivo labelling of brain dopamine D2 receptors using the high-affinity specific D2 agonist (3H)CV 205-502 (1988) Brain Res., 440, pp. 123-128
Brue, T., Pellegrini, I., Gunz, G., Effects of dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine (1992) J Clin Endocrinol Metab., 74, pp. 577-584
Colao, A., Merola, B., Sarnacchiaro, F., Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas (1995) Horm Res., 44, pp. 222-228
Chiodini, P.G., Attanasio, R., Cozzi, R., CV 205-502 in acromegaly (1993) Acta Endocrinol, 128, pp. 389-393. , Copenh
Lombardi, G., Colao, A., Ferone, D., CV 205-502 treatment in therapy-resistant acromegalic patients (1995) Eur J Endocrinol., 132, pp. 559-564
Kwekkeboom, D.J., Lamberts, S.W.J., Long-term treatment with dopamine agonist CV 205-502 of patients with clinically non-functioning, gonadotroph, or α-subunit secreting pituitary adenoma (1992) Clin Endocrinol, 36, pp. 171-176. , Oxf
Brücke, T., Wenger, S., Asenbaum, S., Dopamine D2 receptor imaging and measurements with SPECT (1993) Adv Neurol., 60, pp. 494-500
De Herder, W.W., Reijs, A.E.M., Kwekkeboom, D.J., In vivo imaging of pituitary tumors using a radiolabeled dopamine D2 receptor radioligand (1996) Clin Endocrinol, 45, pp. 755-767. , Oxf
Scillitani, A., Dicembrino, F., Di Fazio, P., In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxybenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas (1995) J Clin Endocrinol Metab., 80, pp. 2523-2525
Verhoeff, N.P., Bemelman, F.J., Wiersinga, W.M., Van Royen, E.A., Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with TSH/PRL-producing pituitary macroadenoma (1993) Eur J Nucl Med., 20, pp. 555-561
Verhoeff, N.P., Van Royen, E.A., Van Royen, N., Dopamine D2-receptor imaging with dynamic I-123 iodo benzamide SPECT in healthy human volunteers (1991) J Nucl Med., 32, pp. 1076-1079
Ebersold, M.J., Quast, L.M., Laws, E.R., Long-term results in transsphenoidal removal of nonfunctioning pituitary adenomas (1986) J Neurosurg., 334, pp. 246-254
Harris, P.E., Afshar, F., Coates, P., The effects of transsphenoidal surgery on endocrine function and visual fields in patients with functionless pituitary adenomas (1989) Q J Med New Series, 71, p. 417
Littley, M.D., Shalet, S.M., Beardwell, C.G., Ahmed, S.R., Applegate, G., Sutton, M.I., Hypopituitarism following external radiotherapy for pituitary tumors in adults (1989) Q J Med New Series, 70, p. 145
Warnet, A., Timsit, J., Chanson, P., The effect of somatostatin analogue on chiasmal dysfunction from pituitary macroadenomas (1989) J Neurosurg., 71, pp. 687-690
De Bruin, T.W.A., Kwekkeboom, D.J., Van't Verlaat, J.W., Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro (1992) J Clin Endocrinol Metab., 75, pp. 1310-1317
Merola, B., Colao, A., Ferone, D., Effects of chronic treatment with octreotide in patients with functionless pituitary adenomas (1993) Horm Res., 40, pp. 149-155
Plöckinger, U., Reichel, M., Fett, U., Saeger, W., Quabbe, H.J., Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: Effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy (1994) J Clin Endocrinol Metab., 79, pp. 1416-1423
Bevan, J.S., Burke, C.W., Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine (1986) Clin Endocrinol, 25, pp. 561-572. , Oxf
Koga, M., Nakao, H., Arao, M., Demonstration of specific dopamine receptors on human pituitary adenomas (1987) Acta Endocrinol, 114, pp. 595-602. , Copenh
De Herder, W.W., Lamberts, S.W.J., Imaging of pituitary tumours (1995) Baillieres Clin Endocrinol Metab., 9, pp. 367-389
Leslie, W.D., Abrams, D.N., Greenberg, C.R., Hobson, D., Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging (1996) J Nucl Med., 37, pp. 1589-1591
Pirker, W., Riedl, M., Luger, A., Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT (1996) J Nucl Med., 37, pp. 1931-1937
Pirker, W., Brücke, T., Riedl, M., Iodine-123-IBZM-SPECT: Studies in 15 patients with pituitary tumors (1994) J Neural Transm., 97, pp. 235-244
Bevan, J. S., Webster, J., Burke, C. W., Scanlon, M. F., Dopamine agonists and pituitary tumor shrinkage (1992) Endocr Rev., 13, pp. 220-24
Chiodini, P. G., Attanasio, R., Cozzi, R., CV 205-502 in acromegaly (1993) Acta Endocrinol, 128, pp. 389-393. , Copenh
Kwekkeboom, D. J., Lamberts, S. W. J., Long-term treatment with dopamine agonist CV 205-502 of patients with clinically non-functioning, gonadotroph, or -subunit secreting pituitary adenoma (1992) Clin Endocrinol, 36, pp. 171-176. , Oxf
Br cke, T., Wenger, S., Asenbaum, S., Dopamine D2 receptor imaging and measurements with SPECT (1993) Adv Neurol., 60, pp. 494-500
De Herder, W. W., Reijs, A. E. M., Kwekkeboom, D. J., In vivo imaging of pituitary tumors using a radiolabeled dopamine D2 receptor radioligand (1996) Clin Endocrinol, 45, pp. 755-767. , Oxf
Verhoeff, N. P., Bemelman, F. J., Wiersinga, W. M., Van Royen, E. A., Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with TSH/PRL-producing pituitary macroadenoma (1993) Eur J Nucl Med., 20, pp. 555-561
Verhoeff, N. P., Van Royen, E. A., Van Royen, N., Dopamine D2-receptor imaging with dynamic I-123 iodo benzamide SPECT in healthy human volunteers (1991) J Nucl Med., 32, pp. 1076-1079
Ebersold, M. J., Quast, L. M., Laws, E. R., Long-term results in transsphenoidal removal of nonfunctioning pituitary adenomas (1986) J Neurosurg., 334, pp. 246-254
Harris, P. E., Afshar, F., Coates, P., The effects of transsphenoidal surgery on endocrine function and visual fields in patients with functionless pituitary adenomas (1989) Q J Med New Series, 71, p. 417
Littley, M. D., Shalet, S. M., Beardwell, C. G., Ahmed, S. R., Applegate, G., Sutton, M. I., Hypopituitarism following external radiotherapy for pituitary tumors in adults (1989) Q J Med New Series, 70, p. 145
De Bruin, T. W. A., Kwekkeboom, D. J., Van't Verlaat, J. W., Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro (1992) J Clin Endocrinol Metab., 75, pp. 1310-1317
Pl ckinger, U., Reichel, M., Fett, U., Saeger, W., Quabbe, H. J., Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: Effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy (1994) J Clin Endocrinol Metab., 79, pp. 1416-1423
Bevan, J. S., Burke, C. W., Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine (1986) Clin Endocrinol, 25, pp. 561-572. , Oxf
De Herder, W. W., Lamberts, S. W. J., Imaging of pituitary tumours (1995) Baillieres Clin Endocrinol Metab., 9, pp. 367-389
Leslie, W. D., Abrams, D. N., Greenberg, C. R., Hobson, D., Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging (1996) J Nucl Med., 37, pp. 1589-1591
Pirker, W., Br cke, T., Riedl, M., Iodine-123-IBZM-SPECT: Studies in 15 patients with pituitary tumors (1994) J Neural Transm., 97, pp. 235-244
Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas
The efficacy of dopaminergic agents in the medical treatment of pituitary adenomas is well known. Quinagolide is a nonergot derivative dopamine agonist, which binds dopamine D2 receptors with high affinity. The treatment with this drug is reported to suppress hormone levels and to cause tumor shrinkage in prolactinomas and in a few GH-secreting pituitary adenomas. In clinically nonfunctioning pituitary adenomas (NFPA), the efficacy of quinagolide treatment is controversial. The scintigraphy of the pituitary region using 123-Imethoxybenzamide (123I-IBZM) allows us to visualize in vivo the expression of dopamine D2 receptors on pituitary tumors. In this study, the pituitary scintigraphy with 123I-IBZM was performed in 14 patients with macroadenoma before starting a long-term treatment with quinagolide: 6 NFPA with high circulating α-subunit levels, 4 PRL-secreting, and 4 GH-secreting adenomas. A 3-point score was used to grade the ligand accumulation within the pituitary adenomas: 0 = negative, 1 = moderate uptake (equal to that recorded in the cerebral cortex), and 2 = intense uptake (equal to that recorded in the basal nuclei). The treatment with quinagolide was carried out at the dose of 0.3-0.6 mg/day for 6-12 months. Clinical, biochemical and hormonal assessment was repeated monthly during the first 3 months, then quarterly. Sellar magnetic resonance imaging was per- formed before and after 6 and 12 months of quinagolide treatment, to evaluate tumor shrinkage (>25% of baseline size). In all 14 patients, a significant positive correlation was found between the degree of 123I- IBZM uptake and the clinical response to quinagolide treatment (r = 0.90; P < 0.001). In particular, the normalization of serum α-subunit and PRL levels, respectively, was achieved in 3 patients with NFPA and in 2 patients with prolactinoma, who showed intense 123I-IBZM uptake in the pituitary region. In 4 of these 5 patients with positive scan, a significant tumor shrinkage occurred between 6 and 12 months after the beginning of quinagolide treatment. In all patients with GH-secreting adenoma, no significant uptake of 123I-IBZM was found and no significant decrease of circulating GH and/or insulin-like growth factor-I levels, and tumor shrinkage was obtained during long-term treatment with quinagolide. In conclusion, the pituitary scintigraphy with 123I-IBZM can be considered a useful tool to indicate adenomas with significant expression of functioning D2 receptors. This innovative technique may predict the response to long-term treatment with quinagolide in patients with NFPA, where the lack of pituitary hormone hypersecretion makes difficult the monitoring of medical treatment efficacy.
The efficacy of dopaminergic agents in the medical treatment of pituitary adenomas is well known. Quinagolide is a nonergot derivative dopamine agonist, which binds dopamine D2 receptors with high affinity. The treatment with this drug is reported to suppress hormone levels and to cause tumor shrinkage in prolactinomas and in a few GH-secreting pituitary adenomas. In clinically nonfunctioning pituitary adenomas (NFPA), the efficacy of quinagolide treatment is controversial. The scintigraphy of the pituitary region using 123-Imethoxybenzamide (123I-IBZM) allows us to visualize in vivo the expression of dopamine D2 receptors on pituitary tumors. In this study, the pituitary scintigraphy with 123I-IBZM was performed in 14 patients with macroadenoma before starting a long-term treatment with quinagolide: 6 NFPA with high circulating α-subunit levels, 4 PRL-secreting, and 4 GH-secreting adenomas. A 3-point score was used to grade the ligand accumulation within the pituitary adenomas: 0 = negative, 1 = moderate uptake (equal to that recorded in the cerebral cortex), and 2 = intense uptake (equal to that recorded in the basal nuclei). The treatment with quinagolide was carried out at the dose of 0.3-0.6 mg/day for 6-12 months. Clinical, biochemical and hormonal assessment was repeated monthly during the first 3 months, then quarterly. Sellar magnetic resonance imaging was per- formed before and after 6 and 12 months of quinagolide treatment, to evaluate tumor shrinkage (>25% of baseline size). In all 14 patients, a significant positive correlation was found between the degree of 123I- IBZM uptake and the clinical response to quinagolide treatment (r = 0.90; P < 0.001). In particular, the normalization of serum α-subunit and PRL levels, respectively, was achieved in 3 patients with NFPA and in 2 patients with prolactinoma, who showed intense 123I-IBZM uptake in the pituitary region. In 4 of these 5 patients with positive scan, a significant tumor shrinkage occurred between 6 and 12 months after the beginning of quinagolide treatment. In all patients with GH-secreting adenoma, no significant uptake of 123I-IBZM was found and no significant decrease of circulating GH and/or insulin-like growth factor-I levels, and tumor shrinkage was obtained during long-term treatment with quinagolide. In conclusion, the pituitary scintigraphy with 123I-IBZM can be considered a useful tool to indicate adenomas with significant expression of functioning D2 receptors. This innovative technique may predict the response to long-term treatment with quinagolide in patients with NFPA, where the lack of pituitary hormone hypersecretion makes difficult the monitoring of medical treatment efficacy.
Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas
| ▼ Clinical Oncology |
Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas
Other filter: ([btitle,keywords] "3 Iodo 6 Methoxybenz ...
Lanzillo R, Di Somma C, Quarantelli M, Carotenuto A, Pivonello C, Moccia M, Cianflone A, Marsili A, Puorro G, Sacca F, Russo CV, De Luca Picione C, Ausiello F, Colao A, Brescia Morra V
* Growth hormone/IGF-1 axis longitudinal evaluation in clinically isolated syndrome patients on interferon beta-1b therapy: stimulation tests and correlations with clinical and radiological conversion to multiple sclerosis (266 views)
Eur J Neurol (ISSN: 1351-5101, 1468-1331electronic, 1351-5101linking), 2017 Feb; 24(2): 446-449.
Impact Factor: 4.621
View Export to BibTeX Export to EndNote
Pisani A, Sabbatini M, Imbriaco M, Riccio E, Rubis N, Prinster A, Perna A, Liuzzi R, Spinelli L, Santangelo M, Remuzzi G, Ruggenenti P
* Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease (280 views)
Clin Gastroenterol H (ISSN: 1542-3565), 2016 Feb 1; N/D: N/D-N/D.
Impact Factor: 7.398
View Export to BibTeX Export to EndNote
De Luca S, Fonti R, Camera L, Salvatore B, Faggiano A, Ciarmiello A, Segreto S, Colao A, Salvatore M, Del Vecchio S
* Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma (334 views)
Ann Nucl Med (ISSN: 0914-7187, 1864-6433, 0914-7187linking), 2016 Jan 11; 30(3): 1-8.
Impact Factor: 1.396
View Export to BibTeX Export to EndNote
Olgiati S, De Rosa A, Quadri M, Criscuolo C, Breedveld GJ, Picillo M, Pappata S, Quarantelli M, Barone P, De Michele G, Bonifati V
* Park20 Caused By Synj1 Homozygous Arg258gln Mutation In A New Italian Family (492 views)
Neurogenetics (ISSN: 1364-6745, 1364-6753), 2014 Aug; 15(3): 183-188.
Impact Factor: 2.884
View Export to BibTeX Export to EndNote
Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, de LucaL, Circelli L, Colantuoni V, Di Sarno A, Carratu AC, Di Roseto CDL, Colao A, Faggiano A
* Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours (501 views)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265), 2014 Jun; 80(6): 850-855.
Impact Factor: 3.457
View Export to BibTeX Export to EndNote
Dynkevich Y, Rother KI, Whitford I, Qureshi S, Galiveeti S, Szulc AL, Danoff A, Breen TL, Kaviani N, Shanik MH, LeRoith D, Vigneri R, Koch CA, Roth J
* Tumors, IGF-2, and Hypoglycemia: Insights From the Clinic, the Laboratory, and the Historical Archive (1999 views)
Endocrine Reviews (ISSN: 0163-769x), 2013 Dec; 34(6): 798-826.
Impact Factor: 19.358
View Export to BibTeX Export to EndNote
Fonti R, Mainolfi C, Anzivino A, Camera L, Faggiano A, Colao A, Salvatore M, Del Vecchio S
* 18F-FDG-PET/CT and 111In-Octreotide SPECT in Patients with Metastatic Medullary Thyroid Carcinoma (270 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
View Export to BibTeX Export to EndNote
Accardo A, Mangiapia G, Paduano L, Morelli G, Tesauro D
* Octreotide labeled aggregates containing platinum complexes as nanovectors for drug delivery (410 views)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2013 Apr; 19(4): 190-197.
Impact Factor: 1.862
View Export to BibTeX Export to EndNote
De Luca S, Fonti R, Palmieri G, Federico P, Del Prete G, Pacelli R, Pace L, De Placido S, Salvatore M, Del Vecchio S
* Combined Imaging With 18f-Fdg-Pet/Ct And 111in-Labeled Octreotide Spect For Evaluation Of Thymic Epithelial Tumors (354 views)
Clin Nucl Med (ISSN: 1536-0229, 0363-3976, 0363-9762), 2013; 38(5): 354-358.
Impact Factor: 2.857
View Export to BibTeX Export to EndNote
Palmieri G, Fonti R, Federico P, Del Prete G, Pacelli R, Pace L, Salvatore M, Del Vecchio S
* Combined 18F-FDG-PET/CT and 111In-Octreotide SPECT for Evaluation of Thymic Epithelial Tumors (272 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2012 Oct; 39: N/D-N/D.
Impact Factor: 5.114
View Export to BibTeX Export to EndNote
Saccà F, Quarantelli M, Rinaldi C, Tucci T, Piro R, Perrotta G, Carotenuto B, Marsili A, Palma V, De Michele G, Brunetti A, Brescia Morra V, Filla A, Salvatore M
* A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results (793 views)
J Neurol (ISSN: 1432-1459, 0340-5354, 1432-1459electronic), 2012 Jan; 259(1): 132-138.
Impact Factor: 3.578
View Export to BibTeX Export to EndNote
Accardo A, Morisco A, Gianolio E, Tesauro D, Mangiapia G, Radulescu A, Brandt A, Morelli G
* Nanoparticles containing octreotide peptides and gadolinium complexes for MRI applications (508 views)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2011 Feb; 17(2): 154-162.
Impact Factor: 1.799
View Export to BibTeX Export to EndNote
Nardelli A, Castaldi E, Ortosecco G, Speranza A, Storto G, Pace L, Salvatore M
* Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90 (541 views)
Applied Radiation And Isotopes (ISSN: 1872-9800, 0969-8043, 0969-8043linking), 2011 Jan; 69(1): 52-55.
Impact Factor: 1.172
View Export to BibTeX Export to EndNote
Lanzillo R, Di Somma C, Quarantelli M, Ventrella G, Vacca G, Liuzzi R, Amato L, Orefice G, Colao A, Brescia Morra V
* Growth Hormone Axis In Early Multiple Sclerosis Patients Before And After 2 Years Treatment With Interferon Beta-1b - An Interim Analysis (275 views)
Proceedings Of The Xlii Meeting Of The Italian Society Of Neurology, 2011; nd: 360-360.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Cittadini A, Saldamarco L, Marra AM, Arcopinto M, Carlomagno G, Imbriaco M, Del Forno D, Vigorito C, Merola B, Oliviero U, Fazio S, Sacca L
* Growth Hormone Deficiency in Patients with Chronic Heart Failure and Beneficial Effects of Its Correction (650 views)
Journal Of Clinical Endocrinology & Metabolism (ISSN: 0021-972x), 2009 Sep; 94(9): 3329-3336.
Impact Factor: 6.202
View Export to BibTeX Export to EndNote
Sacca F, Quarantelli M, Rinaldi C, Tucci T, Piro R, Carotenuto B, Marsili A, Palma V, Bresciamorra V, Brunetti A, De Michele G, Filla A, Salvatore M
* A Double-Blind, Placebo-Controlled, Randomized Trial of Growth Hormone as Add-On Therapy to Riluzole in Patients with Amyotrophic Lateral Sclerosis: Preliminary MRS, Hormonal, and Population Analysis (395 views)
Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2009 Mar 17; 72(11): N/D-N/D.
Impact Factor: 8.172
View Export to BibTeX Export to EndNote
Sacca F, Quarantelli M, Rinaldi C, Tucci T, Piro R, Carotenuto B, Marsili A, Palma V, Bresciamorra V, Brunetti A, De Michele G, Filla A, Salvatore M
* A Randomized Trial of Growth Hormone as Add. On Therapy to Riluzole in Patients with Amyotrophic Lateral Sclerosis (320 views)
Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2009 Mar 17; 76(9): N/D-N/D.
Impact Factor: 8.172
View Export to BibTeX Export to EndNote
Morisco A, Accardo A, Gianolio E, Tesauro D, Benedetti E, Morelli G
* Micelles derivatized with octreotide as potential target-selective contrast agents in MRI (432 views)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2009 Mar; 15(3): 242-250.
Impact Factor: 1.807
View Export to BibTeX Export to EndNote
Zaccaro L, Del Gatto A, Pedone C, Saviano M
* Peptides for tumour therapy and diagnosis: current status and future directions (1177 views)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2009 Mar; 16(7): 780-795.
Impact Factor: 4.708
View Export to BibTeX Export to EndNote
Supuran CT, Di Fiore A, De Simone G
* Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity (572 views)
Expert Opin Emerg Drugsexpert Opinion On Emerging Drugs (ISSN: 1472-8214), 2008 Jun; 13(2): 383-392.
Impact Factor: 3.08
View Export to BibTeX Export to EndNote
Pulcrano M, Camera L, Pagano L, Del Vecchio S, Ferone D, Bodei L, Murgia A, Pace L, Storto G, Paganelli G, Colao A, Salvatore M, Lombardi G, Biondi B
* Usefulness of [(111)In-DTPA(0)] octreotide scintigraphy in a family with von Hippel-Lindau disease (360 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2008 Apr; 31(4): 352-359.
Impact Factor: 1.888
View Export to BibTeX Export to EndNote
De Simone G, Di Fiore A, Supuran CT
* Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? (478 views)
Curr Pharm Des Current Pharmaceutical Design (ISSN: 1381-6128, 1873-4286), 2008 Mar; 14(7): 655-660.
Impact Factor: 4.399
View Export to BibTeX Export to EndNote
Colao A, Di Somma C, Cuocolo A, Spinelli L, Acampa W, Spiezia S, Rota F, Savanelli MC, Lombardi G
* Does a gender-related effect of growth hormone (GH) replacement exist on cardiovascular risk factors, cardiac morphology, and performance and atherosclerosis? Results of a two-year open, prospective study in young adult men and women with severe GH deficiency (450 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2005 Sep; 90(9): 5146-5155.
Impact Factor: 6.02
View Export to BibTeX Export to EndNote
Tauchmanovà L, Pensabene M, Capuano I, Spagnoletti I, Zeppa P, Del Vecchio S, Mainenti PP, De Rosa G, Colao A, Contegiacomo A
* Poorly differentiated small cell neuroendocrine carcinoma localized in three different endocrine glands: Response to chemotherapy and octreotide LAR (334 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2005 Apr; 28(4): 371-378.
Impact Factor: 1.496
View Export to BibTeX Export to EndNote
Savastano S, Pivonello R, Acampa W, Salvatore M, Lombardi G, Colao A, Fenzi G
* Recombinant thyrotropin-induced orbital uptake of [In-111-diethylenetriamine-pentacetic acid-D-phe(1)]octreotide in a patient with inactive Graves' ophthalmopathy (323 views)
Journal Of Clinical Endocrinology & Metabolism (ISSN: 0021-972x), 2005 Apr; 90(4): 2440-2444.
Impact Factor: 6.02
View Export to BibTeX Export to EndNote
Colao A, Di Somma C, Cuocolo A, Filippella M, Rota F, Acampa W, Savastano S, Salvatore M, Lombardi G
* The severity of growth hormone deficiency correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: An observational, case-control study (304 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2004 Dec; 89(12): 5998-6004.
Impact Factor: 5.778
View Export to BibTeX Export to EndNote
Spinelli L, Petretta M, Verderame G, Carbone G, Venetucci AA, Petretta A, Acampa W, Bonaduce D, Colao A, Cuocolo A
* Left ventricular diastolic function and cardiac performance during exercise in patients with acromegaly (435 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2003 Sep; 88(9): 4105-4109.
Impact Factor: 5.873
View Export to BibTeX Export to EndNote
Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, Salvatore M, Lombardi G
* Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide (567 views)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 2003 Feb; 58(2): 169-176.
Impact Factor: 2.767
View Export to BibTeX Export to EndNote
Camera L, Del Vecchio S, Quarantelli M, Ibello F, Pellegrino T, Salvatore M
* Radiolabeled somatostatin analogs in the diagnosis and staging of neuroendocrine tumors (329 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2003; 26(8Suppl): 60-62.
Impact Factor: 1.621
View Export to BibTeX Export to EndNote
Colao A, Spinelli L, Cuocolo A, Spiezia S, Pivonello R, Di Somma C, Bonaduce D, Salvatore M, Lombardi G
* Cardiovascular consequences of early-onset growth hormone excess (422 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2002 Jul; 87(7): 3097-3104.
Impact Factor: 5.199
View Export to BibTeX Export to EndNote
Colao A, Di Somma C, Pivonello R, Cuocolo A, Spinelli L, Bonaduce D, Salvatore M, Lombardi G
* The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: A 12-month prospective study (401 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2002 Mar; 87(3): 1088-1093.
Impact Factor: 5.199
View Export to BibTeX Export to EndNote
Colao A, Di Somma C, Cuocolo A, Spinelli L, Tedesco N, Pivonello R, Bonaduce D, Salvatore M, Lombardi G
* Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients, with GH deficiency (634 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2001 May; 86(5): 1874-1881.
Impact Factor: 5.16
View Export to BibTeX Export to EndNote
Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Morte A, Pivonello R, Salvatore M, Lombardi G
* Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance (347 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2001 Apr; 86(4): 1551-1557.
Impact Factor: 5.16
View Export to BibTeX Export to EndNote
Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G
Cardiovascular effects of depot long-acting somatostatin analog sandostatin LAR in acromegaly (430 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2000 Sep; 85(9): 3132-3140.
Impact Factor: 5.447
View Export to BibTeX Export to EndNote
Marzullo P, Cuocolo A, Ferone D, Pivonello R, Salvatore M, Lombardi G, Colao A
Cardiac effect of thyrotoxicosis in acromegaly (494 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2000 Apr; 85(4): 1426-1432.
Impact Factor: 5.447
View Export to BibTeX Export to EndNote
Colao A, Cuocolo A, Di Somma C, Cerbone G, Della Morte A, Pivonello R, Nicolai E, Salvatore M, Lombardi G
Does the age of onset of growth hormone deficiency affect cardiac performance? A radionuclide angiography study (305 views)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 2000 Apr; 52(4): 447-455.
Impact Factor: 2.922
View Export to BibTeX Export to EndNote
Colao A, Cuocolo A, Di Somma C, Cerbone G, Della Morte A, Nicolai E, Lucci R, Salvatore M, Lombardi G
Impaired cardiac performance in elderly patients with growth hormone deficiency (426 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 1999 Nov; 84(11): 3950-3955.
Impact Factor: 5.805
View Export to BibTeX Export to EndNote
Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte A, Petretta M, Salvatore M, Lombardi G
Impact of patient's age and disease duration on cardiac performance in acromegaly: A radionuclide angiography study (287 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 1999 May; 84(5): 1518-1523.
Impact Factor: 5.805
View Export to BibTeX Export to EndNote
Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa W, Salvatore M, Lombardi G
The pituitary uptake of In-111-DTPA-D-Phe(1)-octreotide in the normal pituitary and in pituitary adenomas (397 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 1999 Mar; 22(3): 176-183.
Impact Factor: 0.957
View Export to BibTeX Export to EndNote
Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Florimonte L, Salvatore M, Lombardi G
Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly (397 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 1999 Jan; 84(1): 17-23.
Impact Factor: 5.805
View Export to BibTeX Export to EndNote
Lastoria S, Vergara E, Palmieri G, Acampa W, Varrella P, Caracò C, Bianco RA, Muto P, Salvatore M
In vivo detection of malignant thymic masses by indium-111-DTPA-D- Phe1-octreotide scintigraphy (428 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1998 Apr; 39(4): 634-639.
Impact Factor: 3.064
View Export to BibTeX Export to EndNote
Longobardi S, Cuocolo A, Merola B, Di Rella F, Colao A, Nicolai E, Cardei S, Salvatore M, Lombardi G
Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency (470 views)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 1998 Feb; 48(2): 137-143.
Impact Factor: 3.101
View Export to BibTeX Export to EndNote
Lombardi G, Colao A, Cuocolo A, Longobardi S, Di Somma C, Orio F, Merola B, Nicolai E, Salvatore M
Cardiological aspects of growth hormone and insulin-like growth factor- (843 views)
J Pediatr Endocrinol Metab (ISSN: 0334-018x), 1997 Nov; 10(6): 553-560.
Impact Factor: 0.481
View Export to BibTeX Export to EndNote
Maurea S, Lastoria S, Caracò C, Klain M, Varrella P, Acampa W, Muto P, Salvatore M
The role of radiolabeled somatostatin analogs in adrenal imaging (377 views)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897), 1996 Sep; 23(6): 677-680.
Impact Factor: 1.042
View Export to BibTeX Export to EndNote
Lastoria S, Maurea S, Vergara E, Acampa W, Varrella P, Klain M, Muto P, Bernardy JD, Salvatore M
Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors (336 views)
Q J Nucl Med (ISSN: 1125-0135, 1124-3937), 1995 Dec; 39(4Suppl1): 145-149.
Impact Factor: 2.125
View Export to BibTeX Export to EndNote
Palmeieri G, Lastoria S, Vergara E, Varrella P, Acampa W, Salvatore M, Bianco AR
Diagnosis and treatment of thymoma by octreotide (234 views)
Meetingproceedings Of The American Association For Cancer Research Annual (ISSN: 0197-016x), 1995; 36(0): N/D-N/D.
Impact Factor: 0
View Export to BibTeX Export to EndNote
LASTORIA S, COLAO A, VERGARA E, FERONE D, VARRELLA P, MEROLA B, ACAMPA W, LOMBARDI G, SALVATORE M
IN-111 OCTREOTIDE UPTAKE LEVELS IN PITUITARY-ADENOMAS TO PREDICT THE RESPONSIVENESS TO CHRONIC OCTREOTIDE TREATMENT (240 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1994 May; 35(5): N/D-N/D.
Impact Factor: 3.491
View Export to BibTeX Export to EndNote
LASTORIA S, VERGARA E, VARRELLA P, ACAMPA W, PALMIERI G, SALVATORE M
IN-VIVO DETECTION OF NEW DISEASES EXPRESSING SOMATOSTATIN RECEPTORS BY IN-111 OCTREOTIDE (267 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1994 May; 35(5): N/D-N/D.
Impact Factor: 3.491
View Export to BibTeX Export to EndNote
LASTORIA S, VERGARA E, VARRELLA P, ACAMPA W, PALMIERI G, SALVATORE M
IN-VIVO DETECTION OF NEW NEOPLASTIC LESIONS EXPRESSING SOMATOSTATIN RECEPTORS USING IN-111 OCTREOTIDE (293 views)
Posters Tomes 1 4proceedings Of The Xvi International Cancer Congress Free Papers And, 1994; N/D: N/D-N/D.
Impact Factor: 0
View Export to BibTeX Export to EndNote
* Growth hormone/IGF-1 axis longitudinal evaluation in clinically isolated syndrome patients on interferon beta-1b therapy: stimulation tests and correlations with clinical and radiological conversion to multiple sclerosis (266 views)
Eur J Neurol (ISSN: 1351-5101, 1468-1331electronic, 1351-5101linking), 2017 Feb; 24(2): 446-449.
Impact Factor: 4.621
View Export to BibTeX Export to EndNote
Pisani A, Sabbatini M, Imbriaco M, Riccio E, Rubis N, Prinster A, Perna A, Liuzzi R, Spinelli L, Santangelo M, Remuzzi G, Ruggenenti P
* Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease (280 views)
Clin Gastroenterol H (ISSN: 1542-3565), 2016 Feb 1; N/D: N/D-N/D.
Impact Factor: 7.398
View Export to BibTeX Export to EndNote
De Luca S, Fonti R, Camera L, Salvatore B, Faggiano A, Ciarmiello A, Segreto S, Colao A, Salvatore M, Del Vecchio S
* Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma (334 views)
Ann Nucl Med (ISSN: 0914-7187, 1864-6433, 0914-7187linking), 2016 Jan 11; 30(3): 1-8.
Impact Factor: 1.396
View Export to BibTeX Export to EndNote
Olgiati S, De Rosa A, Quadri M, Criscuolo C, Breedveld GJ, Picillo M, Pappata S, Quarantelli M, Barone P, De Michele G, Bonifati V
* Park20 Caused By Synj1 Homozygous Arg258gln Mutation In A New Italian Family (492 views)
Neurogenetics (ISSN: 1364-6745, 1364-6753), 2014 Aug; 15(3): 183-188.
Impact Factor: 2.884
View Export to BibTeX Export to EndNote
Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V, de LucaL, Circelli L, Colantuoni V, Di Sarno A, Carratu AC, Di Roseto CDL, Colao A, Faggiano A
* Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours (501 views)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265), 2014 Jun; 80(6): 850-855.
Impact Factor: 3.457
View Export to BibTeX Export to EndNote
Dynkevich Y, Rother KI, Whitford I, Qureshi S, Galiveeti S, Szulc AL, Danoff A, Breen TL, Kaviani N, Shanik MH, LeRoith D, Vigneri R, Koch CA, Roth J
* Tumors, IGF-2, and Hypoglycemia: Insights From the Clinic, the Laboratory, and the Historical Archive (1999 views)
Endocrine Reviews (ISSN: 0163-769x), 2013 Dec; 34(6): 798-826.
Impact Factor: 19.358
View Export to BibTeX Export to EndNote
Fonti R, Mainolfi C, Anzivino A, Camera L, Faggiano A, Colao A, Salvatore M, Del Vecchio S
* 18F-FDG-PET/CT and 111In-Octreotide SPECT in Patients with Metastatic Medullary Thyroid Carcinoma (270 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
View Export to BibTeX Export to EndNote
Accardo A, Mangiapia G, Paduano L, Morelli G, Tesauro D
* Octreotide labeled aggregates containing platinum complexes as nanovectors for drug delivery (410 views)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2013 Apr; 19(4): 190-197.
Impact Factor: 1.862
View Export to BibTeX Export to EndNote
De Luca S, Fonti R, Palmieri G, Federico P, Del Prete G, Pacelli R, Pace L, De Placido S, Salvatore M, Del Vecchio S
* Combined Imaging With 18f-Fdg-Pet/Ct And 111in-Labeled Octreotide Spect For Evaluation Of Thymic Epithelial Tumors (354 views)
Clin Nucl Med (ISSN: 1536-0229, 0363-3976, 0363-9762), 2013; 38(5): 354-358.
Impact Factor: 2.857
View Export to BibTeX Export to EndNote
Palmieri G, Fonti R, Federico P, Del Prete G, Pacelli R, Pace L, Salvatore M, Del Vecchio S
* Combined 18F-FDG-PET/CT and 111In-Octreotide SPECT for Evaluation of Thymic Epithelial Tumors (272 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2012 Oct; 39: N/D-N/D.
Impact Factor: 5.114
View Export to BibTeX Export to EndNote
Saccà F, Quarantelli M, Rinaldi C, Tucci T, Piro R, Perrotta G, Carotenuto B, Marsili A, Palma V, De Michele G, Brunetti A, Brescia Morra V, Filla A, Salvatore M
* A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results (793 views)
J Neurol (ISSN: 1432-1459, 0340-5354, 1432-1459electronic), 2012 Jan; 259(1): 132-138.
Impact Factor: 3.578
View Export to BibTeX Export to EndNote
Accardo A, Morisco A, Gianolio E, Tesauro D, Mangiapia G, Radulescu A, Brandt A, Morelli G
* Nanoparticles containing octreotide peptides and gadolinium complexes for MRI applications (508 views)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2011 Feb; 17(2): 154-162.
Impact Factor: 1.799
View Export to BibTeX Export to EndNote
Nardelli A, Castaldi E, Ortosecco G, Speranza A, Storto G, Pace L, Salvatore M
* Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90 (541 views)
Applied Radiation And Isotopes (ISSN: 1872-9800, 0969-8043, 0969-8043linking), 2011 Jan; 69(1): 52-55.
Impact Factor: 1.172
View Export to BibTeX Export to EndNote
Lanzillo R, Di Somma C, Quarantelli M, Ventrella G, Vacca G, Liuzzi R, Amato L, Orefice G, Colao A, Brescia Morra V
* Growth Hormone Axis In Early Multiple Sclerosis Patients Before And After 2 Years Treatment With Interferon Beta-1b - An Interim Analysis (275 views)
Proceedings Of The Xlii Meeting Of The Italian Society Of Neurology, 2011; nd: 360-360.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Cittadini A, Saldamarco L, Marra AM, Arcopinto M, Carlomagno G, Imbriaco M, Del Forno D, Vigorito C, Merola B, Oliviero U, Fazio S, Sacca L
* Growth Hormone Deficiency in Patients with Chronic Heart Failure and Beneficial Effects of Its Correction (650 views)
Journal Of Clinical Endocrinology & Metabolism (ISSN: 0021-972x), 2009 Sep; 94(9): 3329-3336.
Impact Factor: 6.202
View Export to BibTeX Export to EndNote
Sacca F, Quarantelli M, Rinaldi C, Tucci T, Piro R, Carotenuto B, Marsili A, Palma V, Bresciamorra V, Brunetti A, De Michele G, Filla A, Salvatore M
* A Double-Blind, Placebo-Controlled, Randomized Trial of Growth Hormone as Add-On Therapy to Riluzole in Patients with Amyotrophic Lateral Sclerosis: Preliminary MRS, Hormonal, and Population Analysis (395 views)
Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2009 Mar 17; 72(11): N/D-N/D.
Impact Factor: 8.172
View Export to BibTeX Export to EndNote
Sacca F, Quarantelli M, Rinaldi C, Tucci T, Piro R, Carotenuto B, Marsili A, Palma V, Bresciamorra V, Brunetti A, De Michele G, Filla A, Salvatore M
* A Randomized Trial of Growth Hormone as Add. On Therapy to Riluzole in Patients with Amyotrophic Lateral Sclerosis (320 views)
Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2009 Mar 17; 76(9): N/D-N/D.
Impact Factor: 8.172
View Export to BibTeX Export to EndNote
Morisco A, Accardo A, Gianolio E, Tesauro D, Benedetti E, Morelli G
* Micelles derivatized with octreotide as potential target-selective contrast agents in MRI (432 views)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2009 Mar; 15(3): 242-250.
Impact Factor: 1.807
View Export to BibTeX Export to EndNote
Zaccaro L, Del Gatto A, Pedone C, Saviano M
* Peptides for tumour therapy and diagnosis: current status and future directions (1177 views)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2009 Mar; 16(7): 780-795.
Impact Factor: 4.708
View Export to BibTeX Export to EndNote
Supuran CT, Di Fiore A, De Simone G
* Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity (572 views)
Expert Opin Emerg Drugsexpert Opinion On Emerging Drugs (ISSN: 1472-8214), 2008 Jun; 13(2): 383-392.
Impact Factor: 3.08
View Export to BibTeX Export to EndNote
Pulcrano M, Camera L, Pagano L, Del Vecchio S, Ferone D, Bodei L, Murgia A, Pace L, Storto G, Paganelli G, Colao A, Salvatore M, Lombardi G, Biondi B
* Usefulness of [(111)In-DTPA(0)] octreotide scintigraphy in a family with von Hippel-Lindau disease (360 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2008 Apr; 31(4): 352-359.
Impact Factor: 1.888
View Export to BibTeX Export to EndNote
De Simone G, Di Fiore A, Supuran CT
* Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs? (478 views)
Curr Pharm Des Current Pharmaceutical Design (ISSN: 1381-6128, 1873-4286), 2008 Mar; 14(7): 655-660.
Impact Factor: 4.399
View Export to BibTeX Export to EndNote
Colao A, Di Somma C, Cuocolo A, Spinelli L, Acampa W, Spiezia S, Rota F, Savanelli MC, Lombardi G
* Does a gender-related effect of growth hormone (GH) replacement exist on cardiovascular risk factors, cardiac morphology, and performance and atherosclerosis? Results of a two-year open, prospective study in young adult men and women with severe GH deficiency (450 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2005 Sep; 90(9): 5146-5155.
Impact Factor: 6.02
View Export to BibTeX Export to EndNote
Tauchmanovà L, Pensabene M, Capuano I, Spagnoletti I, Zeppa P, Del Vecchio S, Mainenti PP, De Rosa G, Colao A, Contegiacomo A
* Poorly differentiated small cell neuroendocrine carcinoma localized in three different endocrine glands: Response to chemotherapy and octreotide LAR (334 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2005 Apr; 28(4): 371-378.
Impact Factor: 1.496
View Export to BibTeX Export to EndNote
Savastano S, Pivonello R, Acampa W, Salvatore M, Lombardi G, Colao A, Fenzi G
* Recombinant thyrotropin-induced orbital uptake of [In-111-diethylenetriamine-pentacetic acid-D-phe(1)]octreotide in a patient with inactive Graves' ophthalmopathy (323 views)
Journal Of Clinical Endocrinology & Metabolism (ISSN: 0021-972x), 2005 Apr; 90(4): 2440-2444.
Impact Factor: 6.02
View Export to BibTeX Export to EndNote
Colao A, Di Somma C, Cuocolo A, Filippella M, Rota F, Acampa W, Savastano S, Salvatore M, Lombardi G
* The severity of growth hormone deficiency correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: An observational, case-control study (304 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2004 Dec; 89(12): 5998-6004.
Impact Factor: 5.778
View Export to BibTeX Export to EndNote
Spinelli L, Petretta M, Verderame G, Carbone G, Venetucci AA, Petretta A, Acampa W, Bonaduce D, Colao A, Cuocolo A
* Left ventricular diastolic function and cardiac performance during exercise in patients with acromegaly (435 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2003 Sep; 88(9): 4105-4109.
Impact Factor: 5.873
View Export to BibTeX Export to EndNote
Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, Salvatore M, Lombardi G
* Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide (567 views)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 2003 Feb; 58(2): 169-176.
Impact Factor: 2.767
View Export to BibTeX Export to EndNote
Camera L, Del Vecchio S, Quarantelli M, Ibello F, Pellegrino T, Salvatore M
* Radiolabeled somatostatin analogs in the diagnosis and staging of neuroendocrine tumors (329 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2003; 26(8Suppl): 60-62.
Impact Factor: 1.621
View Export to BibTeX Export to EndNote
Colao A, Spinelli L, Cuocolo A, Spiezia S, Pivonello R, Di Somma C, Bonaduce D, Salvatore M, Lombardi G
* Cardiovascular consequences of early-onset growth hormone excess (422 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2002 Jul; 87(7): 3097-3104.
Impact Factor: 5.199
View Export to BibTeX Export to EndNote
Colao A, Di Somma C, Pivonello R, Cuocolo A, Spinelli L, Bonaduce D, Salvatore M, Lombardi G
* The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: A 12-month prospective study (401 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2002 Mar; 87(3): 1088-1093.
Impact Factor: 5.199
View Export to BibTeX Export to EndNote
Colao A, Di Somma C, Cuocolo A, Spinelli L, Tedesco N, Pivonello R, Bonaduce D, Salvatore M, Lombardi G
* Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients, with GH deficiency (634 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2001 May; 86(5): 1874-1881.
Impact Factor: 5.16
View Export to BibTeX Export to EndNote
Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Morte A, Pivonello R, Salvatore M, Lombardi G
* Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance (347 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2001 Apr; 86(4): 1551-1557.
Impact Factor: 5.16
View Export to BibTeX Export to EndNote
Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G
Cardiovascular effects of depot long-acting somatostatin analog sandostatin LAR in acromegaly (430 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2000 Sep; 85(9): 3132-3140.
Impact Factor: 5.447
View Export to BibTeX Export to EndNote
Marzullo P, Cuocolo A, Ferone D, Pivonello R, Salvatore M, Lombardi G, Colao A
Cardiac effect of thyrotoxicosis in acromegaly (494 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2000 Apr; 85(4): 1426-1432.
Impact Factor: 5.447
View Export to BibTeX Export to EndNote
Colao A, Cuocolo A, Di Somma C, Cerbone G, Della Morte A, Pivonello R, Nicolai E, Salvatore M, Lombardi G
Does the age of onset of growth hormone deficiency affect cardiac performance? A radionuclide angiography study (305 views)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 2000 Apr; 52(4): 447-455.
Impact Factor: 2.922
View Export to BibTeX Export to EndNote
Colao A, Cuocolo A, Di Somma C, Cerbone G, Della Morte A, Nicolai E, Lucci R, Salvatore M, Lombardi G
Impaired cardiac performance in elderly patients with growth hormone deficiency (426 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 1999 Nov; 84(11): 3950-3955.
Impact Factor: 5.805
View Export to BibTeX Export to EndNote
Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte A, Petretta M, Salvatore M, Lombardi G
Impact of patient's age and disease duration on cardiac performance in acromegaly: A radionuclide angiography study (287 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 1999 May; 84(5): 1518-1523.
Impact Factor: 5.805
View Export to BibTeX Export to EndNote
Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa W, Salvatore M, Lombardi G
The pituitary uptake of In-111-DTPA-D-Phe(1)-octreotide in the normal pituitary and in pituitary adenomas (397 views)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 1999 Mar; 22(3): 176-183.
Impact Factor: 0.957
View Export to BibTeX Export to EndNote
Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Florimonte L, Salvatore M, Lombardi G
Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly (397 views)
J Clin Endocrinol Metab (ISSN: 0021-972x), 1999 Jan; 84(1): 17-23.
Impact Factor: 5.805
View Export to BibTeX Export to EndNote
Lastoria S, Vergara E, Palmieri G, Acampa W, Varrella P, Caracò C, Bianco RA, Muto P, Salvatore M
In vivo detection of malignant thymic masses by indium-111-DTPA-D- Phe1-octreotide scintigraphy (428 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1998 Apr; 39(4): 634-639.
Impact Factor: 3.064
View Export to BibTeX Export to EndNote
Longobardi S, Cuocolo A, Merola B, Di Rella F, Colao A, Nicolai E, Cardei S, Salvatore M, Lombardi G
Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency (470 views)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 1998 Feb; 48(2): 137-143.
Impact Factor: 3.101
View Export to BibTeX Export to EndNote
Lombardi G, Colao A, Cuocolo A, Longobardi S, Di Somma C, Orio F, Merola B, Nicolai E, Salvatore M
Cardiological aspects of growth hormone and insulin-like growth factor- (843 views)
J Pediatr Endocrinol Metab (ISSN: 0334-018x), 1997 Nov; 10(6): 553-560.
Impact Factor: 0.481
View Export to BibTeX Export to EndNote
Maurea S, Lastoria S, Caracò C, Klain M, Varrella P, Acampa W, Muto P, Salvatore M
The role of radiolabeled somatostatin analogs in adrenal imaging (377 views)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897), 1996 Sep; 23(6): 677-680.
Impact Factor: 1.042
View Export to BibTeX Export to EndNote
Lastoria S, Maurea S, Vergara E, Acampa W, Varrella P, Klain M, Muto P, Bernardy JD, Salvatore M
Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors (336 views)
Q J Nucl Med (ISSN: 1125-0135, 1124-3937), 1995 Dec; 39(4Suppl1): 145-149.
Impact Factor: 2.125
View Export to BibTeX Export to EndNote
Palmeieri G, Lastoria S, Vergara E, Varrella P, Acampa W, Salvatore M, Bianco AR
Diagnosis and treatment of thymoma by octreotide (234 views)
Meetingproceedings Of The American Association For Cancer Research Annual (ISSN: 0197-016x), 1995; 36(0): N/D-N/D.
Impact Factor: 0
View Export to BibTeX Export to EndNote
LASTORIA S, COLAO A, VERGARA E, FERONE D, VARRELLA P, MEROLA B, ACAMPA W, LOMBARDI G, SALVATORE M
IN-111 OCTREOTIDE UPTAKE LEVELS IN PITUITARY-ADENOMAS TO PREDICT THE RESPONSIVENESS TO CHRONIC OCTREOTIDE TREATMENT (240 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1994 May; 35(5): N/D-N/D.
Impact Factor: 3.491
View Export to BibTeX Export to EndNote
LASTORIA S, VERGARA E, VARRELLA P, ACAMPA W, PALMIERI G, SALVATORE M
IN-VIVO DETECTION OF NEW DISEASES EXPRESSING SOMATOSTATIN RECEPTORS BY IN-111 OCTREOTIDE (267 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1994 May; 35(5): N/D-N/D.
Impact Factor: 3.491
View Export to BibTeX Export to EndNote
LASTORIA S, VERGARA E, VARRELLA P, ACAMPA W, PALMIERI G, SALVATORE M
IN-VIVO DETECTION OF NEW NEOPLASTIC LESIONS EXPRESSING SOMATOSTATIN RECEPTORS USING IN-111 OCTREOTIDE (293 views)
Posters Tomes 1 4proceedings Of The Xvi International Cancer Congress Free Papers And, 1994; N/D: N/D-N/D.
Impact Factor: 0
View Export to BibTeX Export to EndNote
49 Records (40 excluding Abstracts).
Total impact factor: 198.417 (164.76 excluding Abstracts).
Total 5 year impact factor: 167.733 (133.124 excluding Abstracts).
Total impact factor: 198.417 (164.76 excluding Abstracts).
Total 5 year impact factor: 167.733 (133.124 excluding Abstracts).
352 views. Last view on Tuesday 30 May 2023, 6:39:50
ibb.cnr.it
